share_log

Xcelerate, Inc. Announces PTO and PCT Filings For Surgical Devices

Xcelerate, Inc. Announces PTO and PCT Filings For Surgical Devices

Xcelerate, Inc. 宣布手术器械的 PTO 和 PCT 申请
Accesswire ·  2023/04/20 08:30

MAULDIN, SC / ACCESSWIRE / April 20, 2023 / Xcelerate, Inc. (OTCQB:XCRT) announced today it filed two utility patent applications under application numbers 18/187,352 and 18/189,441. Additionally, corresponding PCT applications were filed under PCT/US2023/015755 and PCT/US2023/016194. Both applications are claiming priority to Xcelerate's patent application "Surgical Tools with Targeting Guidance", filed under application number 63/323,112 on March 24th, 2022.

南卡罗来纳州莫尔丁/Accesswire/2023 年 4 月 20 日/ Xcelerate, Inc. (OTCQB: XCRT) 今天宣布,它提交了两项实用专利申请,申请编号为18/187,352和189,441。此外,相应的PCT申请是根据PCT/US2023/015755和PCT/US2023/016194提交的。这两项申请都声称拥有Xcelerate的专利申请 “带靶向指导的手术工具” 的优先权,该申请于2022年3月24日以63/323,112号申请提交。

These applications represent the continuation of Xcelerate's stated mission of "utilizing non-medical engineering advancements and applying them to clinical care". The co-inventors of these patent application are Xcelerate Advisory Board members Dr. Anja Glisovic and Dr. Dilan Ellegala.

这些应用代表着Xcelerate既定使命的延续,即 “利用非医学工程进步并将其应用于临床护理”。这些专利申请的共同发明人是Xcelerate顾问委员会成员安雅·格利索维奇博士和迪兰·埃勒加拉博士。

"These filings represent just one facet of our approach of parallel development, testing and IP-protection of our surgical device lines. We are also proud to unveil first images from our In-Tool-Optics prototypes, which are covered by the filed patents." said Michael O'Shea Xcelerate's CEO.

“这些文件只是我们对手术器械系列进行平行开发、测试和知识产权保护的方法的一个方面。我们还很自豪地公布了我们的In-Tool-Optics原型的第一张图片,这些图像受已申请的专利保护。” Xcelerate首席执行官迈克尔·奥谢伊说。

Dr. Anja Glisovic commented, "A first-person view is most intuitive to us, and we naturally gravitate to it, for example, in virtual reality or computer games. With the advent of minimally invasive surgery, it was partly lost in favor of the endoscope's "third-person view" in medicine. With the In-Tool-Optics series of surgical instruments and devices we bring a new "first-person view" to the surgical theatre. By integrating cameras directly into surgical tools, we allow the surgeon to follow and perform the procedure from the tool's perspective. This new viewpoint has the potential to significantly boost precision and speed of surgical procedures and to reduce the space necessary for several procedures. To further improve this, projection of targeting markers as well as illumination are integrated.

安雅·格利索维奇博士评论说:“第一人称视角对我们来说是最直观的,例如,在虚拟现实或电脑游戏中,我们自然会被它吸引。随着微创手术的出现,微创手术在一定程度上被消失了,取而代之的是内窥镜在医学上的 “第三人称视角”。借助 In-Tool-Optics 系列手术器械和设备,我们为手术室带来了新的 “第一人称视角”。通过将摄像头直接集成到手术工具中,我们允许外科医生从工具的角度跟踪和执行手术。这种新视角有可能显著提高外科手术的精度和速度,并减少多项手术所需的空间。为了进一步改善这一点,集成了目标标记的投影和照明。

We are currently working on three different In-Tool-Optic (ITO) product lines, ITO-Responder, ITO-Clinic, and ITO-Infirmary. The names are telling. The ITO-Responder line is geared towards Emergency Responders, e.g. civilian and military paramedics. Their ITO products will be disposable and come with a rugged, reusable display for field use and a lot of inbuilt auto-adjustment features to optimize contrast and illumination. They will also conform with NATO standardizations as well as with US regulations. The images below are from one of our ITO-Responder prototypes. ITO-Clinic has a different focus. It is designed for use in hospitals and operating theatres. Products from this line will allow much more features to be adjusted manually by the surgeon. For example, there will be access to the Color Rendering Index (CRI), which is especially crucial in the red color palette to identify and distinguish blood vessels as well as other methods of graphical postprocessing and measurements. Finally, there will be the ITO-Infirmary line. No one would want to throw away fully functional surgical tools just because there is a newer tool available but at the same time, the newest tools provide desirable benefits for patients and surgeons. Xcelerate is aware of this and address this with the ITO-Infirmary product line, which will allow to retrofit existing surgical tools with the mentioned functionalities. Thereby, we hope to cover and address the market and customer needs in the best way possible.

我们目前正在开发三种不同的 In-Tool-Optic (ITO) 产品线, 伊藤-回应者伊藤诊所,以及 伊藤医务室。名字很有说服力。该 ITO-Responder line 适用于应急人员,例如民用和军事护理人员。他们的 ITO 产品将是一次性的,配备坚固耐用、可重复使用的显示屏,供现场使用,还有许多内置的自动调整功能,可优化对比度和照明。它们还将符合北约的标准化以及美国的法规。以下图片来自我们的其中一张 ITO-Responder 原型。 伊藤诊所 有不同的重点。它专为医院和手术室使用而设计。该系列的产品将允许外科医生手动调整更多功能。例如,可以访问颜色渲染指数(CRI),这在红色调色板中对于识别和区分血管以及其他图形后处理和测量方法尤其重要。最后,将有 伊藤医务室 线。没有人愿意仅仅因为有更新的工具就丢弃功能齐全的手术工具,但与此同时,最新的工具为患者和外科医生提供了理想的好处。Xcelerate 意识到了这一点,并通过以下方法解决了这个问题 伊藤医务室 产品线,这将允许使用上述功能改造现有的手术工具。因此,我们希望以最佳方式涵盖和满足市场和客户需求。

Disposable Clamp with InTool device prototype and Figure 2: View from the tool's perspective, provided by In-Tool- Dime for scale. Optics

带有 InTool 设备原型和图 2:从工具的角度看的一次性夹子,由 In-Tool-Dime 提供,用于缩放。光学

ABOUT XCELERATE INC.

关于 XCELERATE INC.

In May 2020, Xcelerate commenced implementation of a new business plan that encompasses two separate but related businesses within the medical industry, including (i) owning and licensing the rights to various forms of medical equipment and portfolio of patents, patents pending and technology licenses and (ii) development of virtual health technology to assist patients in developing countries obtain medical care by extending the reach of physicians through the use of that technology. For more information visit or contact us at 854-900-2020 or email info@xcelerate.global.

2020年5月,Xcelerate开始实施一项新的业务计划,该计划涵盖医疗行业内两项独立但相关的业务,包括(i)拥有和许可各种形式的医疗设备以及专利、待批专利和技术许可组合的权利;(ii)开发虚拟健康技术,通过使用该技术扩大医生的覆盖范围,帮助发展中国家的患者获得医疗服务。欲了解更多信息,请访问或致电 854-900-2020 联系我们或发送电子邮件至 info@xcelerate.global。

SAFE HARBOR

安全港

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.

本新闻稿可能包含经修订的1934年《证券交易法》(“交易法”)第21E条所指的前瞻性信息,包括所有非历史事实陈述的关于公司、其董事或高级管理人员在以下方面的意图、信念或当前预期的陈述:(i) 公司的融资计划;(ii) 影响公司财务状况或经营业绩的趋势;(iii) 公司的增长战略和运营战略;以及 (iv)申报和支付股息。“可能”、“将”、“将”、“期望”、“估计”、“预期”、“相信”、“打算” 等词及其类似表达方式和变体旨在识别前瞻性陈述。投资者请注意,任何此类前瞻性陈述都不能保证未来的业绩,并且涉及风险和不确定性,其中许多风险和不确定性超出了公司的控制能力,实际业绩可能与前瞻性陈述中的预测存在重大差异 由于 各种因素。

SOURCE: Xcelerate, Inc.

来源: Xcelerate, Inc.


View source version on accesswire.com:
在 accesswire.com 上查看源代码版本:

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发